A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)
Latest Information Update: 10 Oct 2023
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms Affirm-AHF
- Sponsors Vifor; Vifor Pharma
- 28 Aug 2023 Results investigating the interaction between sex and the effects of FCM vs placebo on clinical outcomes, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 13 Apr 2023 Results (n=1107) of a sub-group analysis assessing association between hemoglobin levels and FCM treatment effects published in the Circulation
- 23 Jul 2022 Results published in the European Journal of Heart Failure